Nuvectis Pharma, Inc.
US ˙ NasdaqCM ˙ US67080T1088

SecurityNVCT / Nuvectis Pharma, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership124,212 shares
Latest Disclosed Value $ 960,159
Northern Trust Corp reports 6.71% increase in ownership of NVCT / Nuvectis Pharma, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 124,212 shares of Nuvectis Pharma, Inc. (US:NVCT) valued at $960,159 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 116,405 shares of Nuvectis Pharma, Inc.. This represents a change in shares of 6.71% during the quarter. The current value of the position is $1,184,982 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F NUVECTIS PHARMA COM 67080T108 124,212 7,807 6.71 960 9.34 0.0001
2026-02-17 2025-12-31 13F NUVECTIS PHARMA COM 67080T108 116,405 9,764 9.16 879 36.97 0.0001
2025-11-14 2025-09-30 13F NUVECTIS PHARMA COM 67080T108 106,641 -3,176 -2.89 642 -21.83 0.0001
2025-08-13 2025-06-30 13F NUVECTIS PHARMA COM 67080T108 109,817 71,759 188.55 820 121.02 0.0001
2025-05-13 2025-03-31 13F NUVECTIS PHARMA COM 67080T108 38,058 12,333 47.94 372 166.91 0.0001
2025-02-14 2024-12-31 13F NUVECTIS PHARMA COM 67080T108 25,725 10,472 68.66 139 46.32 0.0000
2024-11-13 2024-09-30 13F NUVECTIS PHARMA COM 67080T108 15,253 -34,574 -69.39 96 -69.84 0.0000
2024-08-14 2024-06-30 13F NUVECTIS PHARMA COM 67080T108 49,827 -12,270 -19.76 315 -38.11 0.0001
2024-05-14 2024-03-31 13F NUVECTIS PHARMA COM 67080T108 62,097 523 0.85 509 -0.78 0.0001
2024-02-13 2023-12-31 13F NUVECTIS PHARMA COM 67080T108 61,574 6,887 12.59 514 -27.13 0.0001
2023-11-13 2023-09-30 13F NUVECTIS PHARMA COM 67080T108 54,687 1,053 1.96 705 -17.76 0.0001
2023-08-11 2023-06-30 13F NUVECTIS PHARMA COM 67080T108 53,634 53,634 857 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.